MAPT and Alzheimer disease: When applied to preclinical (secondary prevention) and clinical (treatment) trial scenarios on Alzheimer’s disease, our data-driven framework BioDisCVR discovered ratio-based tau PET biomarkers that are vastly superior to previous work.